NC-DOLE
19.1.2022 18:59:12 CET | Business Wire | Press release
The American-Costa Rican Chamber of Commerce (AmCham) recognized Dole through its daughter company, Standard Fruit Company de Costa Rica S.A., with the Social Responsibility in Action Award in the Employees Category for their project "De la Mano con Dole" — which loosely translates to "Hand-in-Hand with Dole". This year marks the 25th anniversary of the award which was given December 8, 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220119005875/en/
The Hand-in-Hand with Dole project is an initiative that works towards positively impacting the social development of Standard Fruit Company of Costa Rica (aka Dole Costa Rica) employees and their families, using the Business Multidimensional Business Index (bMPI) methodology developed by the University of Oxford.
The bMPI methodology seeks to measure poverty—not only from the traditional way of per capita income —but also by incorporating dimensions such as, access to health, education, housing, work, social protection and 16 other key indicators. This allows the organization to identify gaps in social programs and work towards solving the multidimensional poverty issues confronted by their employees and their relatives.
Dole is the first agribusiness company in the world to apply the bMPI methodology to address the challenges of social development.
During the diagnostic stage of implementation, Dole Costa Rica achieved a participation rate of 87% in response to socioeconomic surveys among its more than 5300 employees, ranking near the highest level of participation among the companies that have applied the method in the country.
Analysis of the discovered “deficiencies” refocused short-term priorities of the company towards the prevention of disease and the health of our employees at the onset of Covid, to longer term strategies of social protection and health. At the end of September 2021, 500 gaps had been closed.
“We are very proud of being the first banana and pineapple producer to implement this system and seeing such positive results for our employees and families here in Costa Rica,” said Mr. Renato Acuña, President of Dole Fresh Fruit Latin America. “The strategies developed in this program, including social counseling and community care projects, seek to meet needs and provide the necessary capacities for better human development.”
For this project, Dole management has prioritized addressing the following needs: people without health insurance; people with disabilities not receiving state assistance; older adults without a pension, people out of the workforce due to family obligations; and households without drinking water.
In applying findings, Dole has established strategic alliances with Horizonte Positivo, a local NGO that leads the implementation of bMPI in Costa Rica, and with Sophia Oxford, an international non-profit organization that seeks to impact the social investment of companies and the lives of their employees. These third-party interpretations and analyses of results, and the proposal of solutions that can positively affect the reduction of multidimensional poverty, are essential to best practices in solution implementation.
In 2020, Dole introduced its three-pillared Sustainability Framework, The Dole Way , and its ongoing commitment For Food, For Nature and For People. Just as Dole Costa Rica was a pioneer more than 20 years ago in the development of global environmental management systems in agriculture to frame its efforts 'For Nature'; at the beginning of this decade the company intends through this project, to innovate in the establishment of a social development platform focused on its most important resource: 'For People'."
About Dole
Dole plc is one of the world’s largest producers and marketers of high-quality fresh fruit and fresh vegetables. Dole is an industry leader in many of the products it sells, as well as in nutrition education and research. For more information, please visit www.dole.com or www.doleplc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220119005875/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
